Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT01273337

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Aldagen (from the registry)
Registry
  • NCT NCT01273337
Other papers using this trial's data
  • A Phase 2 Randomized, Sham-Controlled Trial of Internal Carotid Artery Infusion of Autologous Bone Marrow-Derived ALD-401 Cells in Patients With Recent Stable Ischemic Stroke (RECOVER-Stroke) Circulation, 2019-01-08 DOI, PubMed 30586746

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01273337. Randomized; quadruple masking; primary purpose treatment. Start 2011-03 (registry gives no type); primary completion 2014-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects
Condition
Stroke
Condition
Stroke in Middle Cerebral Artery (MCA)
Intervention (Biological)
ALD-401
Intervention (Procedure)
Sham Procedure
Lead sponsor
Aldagen (class: industry)

Record details

Record id
cardio:ct-nct01273337
Content hash
df6274daa35178bdbe17a6f85d597f25c1b3ed08b27682ebe8cecf6d035c1cdb